Abstract
Purpose
Long-term survivors of germ cell tumours (GCT) are at increased risk of cardiovascular morbidity. We investigated the use of tobacco in patients after therapy for GCT.
Methods
Four hundred and seventy-four patients treated between 1979 and 2000 at the University of Munich were asked to complete a self-report questionnaire on psychosocial dimensions which included items on tobacco smoking before and after treatment of GCT.
Results
Three hundred and forty-one patients (72%) returned a completed questionnaire. The median follow-up period was 9.6 years. 160 of 341 patients (47%) reported to smoke at the time of GCT diagnosis. Of those, 134 (84%) had changed their smoking behavior with 32 patients (20%) having reduced, 56 (35%) having intermittently quitted and 46 (29%) having definitively quitted smoking. Patients reduced or stopped smoking irrespective of tumour histology, tumour stage, whether they had received chemotherapy or not, and irrespective of the number of chemotherapy courses applied.
Conclusion
Most patients changed their habit of tobacco smoking after diagnosis and treatment of GCT but only a minority of patients are sustained quitters. Patients with GCT should be strongly encouraged to stop smoking or to participate in smoking cessation programs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group (2005) The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142:233–239
Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923–2932
Brandon T (2001) Behavioral tobacco cessation treatments: yesterday`s news or tomorrow`s headlines?. J Clin Oncol 19(18suppl):64S–68S
Fegg MJ, Gerl A, Vollmer TC, Gruber U, Jost C, Meiler S, Hiddemann W (2003) Subjective quality of life and sexual functioning after germ-cell tumour therapy. Br J Cancer 89: 2202–2206
Gerl A (1998) Does chemotherapy for testicular cancer increase cardiovascular risk? In: Jones WG, Aplleyard I, Harnden P, Joffe JK (eds) Germ cell tumors, IV. John Libbey & Co Ltd, London pp 397–400
Gerl A (2000) Cisplatin-based chemotherapy of testicular cancer—two decades after a major breakthrough. Onkologie 23:106–111
Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H, van Ittersum E, Verschuren WM, Kromhout D, Sluiter WJ, Mulder NH, de Vries EG (1992) Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 116:709–715
Gritz E, Carr C, Rapkin D, Abemayor E, Chang LJ, Wong WK, Belin TK, Calcaterra T, Robbins KT, Chonkich G (1993) Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomark Prev 2:261–270
International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523
Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, Kikuchi S, Koizumi A, Wada Y, Kondo T, Inaba Y, Tamakoshi A, JACC Study Group (2005) Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol 161:170–179
Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1993) Smoking cessation and decreased risk of stroke in women. JAMA 269:232–236
Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EGE, Willemse PBH, Mulder NH, van den Berg MP, Schraffordt Koops H, Sleijfer DT (2000) Cardivascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–1732
Mokdad A, Marks J, Stroup D, Gerberding J (2004) Actual causes of death in the United States, 2000. JAMA 291:1238–1245
Newcomb P, Carbone P (1992) The health consequences of smoking. Cancer Med Clin North Am 76:305–331
Rosal MC, Ockene JK, Ma Y, Hebert JR, Ockene IS, Merriam P, Hurley TG (1998) Coronary artery smoking intervention study (CASIS): 5-year follow-up. Health Psychol 17:476–478
Stoter G, Koopman A, Vendrik CPJ, Struyvenberg A, Sleyfer DT; Willemse PHB, Schraffordt Koops H, van Oosterom AT, ten Bokkel Huinink WW, Pinedo HM (1989) Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 7:1099–1104
Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Möckel C, Seeber S, Scheuelen ME (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13:229–236
Vaughn DJ, Gignac GA, Meadows AT (2002) Long-term medical care of testicular cancer survivors. Ann Intern Med 136:463–570
Wannamethee SG, Shaper AG, Whincup PH, Walker M (1995) Smoking cessation and the risk of stroke in middle-aged men. JAMA 274:155–160
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hentrich, M., Fegg, M.J., Meiler, S. et al. Smoking cessation in long-term survivors of germ cell tumour. J Cancer Res Clin Oncol 132, 557–560 (2006). https://doi.org/10.1007/s00432-006-0102-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-006-0102-z